Dicerna Pharmaceuticals reported $-17072000 in Net Income for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acceleron Pharma XLRN:US $ -70.46M 6.94M
Alnylam Pharmaceuticals ALNY:US $ -204.51M 14.96M
Amgen AMGN:US $ 1884M 1420M
Arrowhead Research ARWR:US $ -63374000 33.45M
Biogen BIIB:US $ 329.2M 119.3M
Bluebird Bio BLUE:US $ -216.82M 24.89M
Dicerna Pharmaceuticals DRNA:US $ -17.07M 23.74M
Exelixis EXEL:US $ 38.2M 57.89M
Gilead Sciences GILD:US $ 2592M 1070M
GlaxoSmithKline GSK:LN 1168M 227M
Immunogen IMGN:US $ -37.34M 6.6M
Intercept Pharmaceuticals ICPT:US $ -3.63M 7.46M
IONIS PHARMACEUT IONS:US $ -82M 1.12M
Karyopharm Therapeutics KPTI:US $ -51812000 1.77M
Lexicon Pharmaceuticals LXRX:US $ -23.12M 5.06M
Macrogenics MGNX:US $ -52.89M 12.95M
Merk MRK:US $ 4567M 3022M
Mirati Therapeutics MRTX:US $ -80.05M 86.38M
Pfizer PFE:US $ 8146M 2582M
Regeneron Pharmaceuticals REGN:US $ 1632.2M 1466.7M
Ultragenyx Pharmaceutical RARE:US $ -73M 49.43M